HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

7-methylthiomethylpaclitaxel (BMS 184476)

Also Known As:

BMS 184476; 7-methylthiomethyl-paclitaxel; BMS-184476; BMS184476

Networked: 10 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - Taxoids: 2650
        7-methylthiomethylpaclitaxel: 10
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclodecanes
        Taxoids: 2650
        7-methylthiomethylpaclitaxel: 10

Experts

1.	Voi, M: 2 articles (04/2005 - 03/2004)
2.	Gallant, Gilles: 2 articles (11/2003 - 09/2002)
3.	Alberola, V: 1 article (04/2005)
4.	Artal, A: 1 article (04/2005)
5.	Astier, L: 1 article (04/2005)
6.	Baselga, J: 1 article (04/2005)
7.	Blasco, A: 1 article (04/2005)
8.	Camps, C: 1 article (04/2005)
9.	Carrato, A: 1 article (04/2005)
10.	Felip, E: 1 article (04/2005)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/01/2005 - "Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer." 04/01/2005 - "The purpose of this study was to evaluate the tolerability and efficacy of BMS-184476, an analog of paclitaxel, in patients with advanced non-small-cell lung cancer (NSCLC) progressing or relapsing following at least one prior chemotherapy regimen. "
2.	Neoplasms (Cancer) 03/01/2004 - "Adult patients with advanced solid malignancies received escalating doses of BMS-184476 infused over 1 h after bolus Doxo. " 09/01/2002 - "Adult patients with solid tumors received BMS-184476 i.v. on days 1, 8, and 15 without premedication. " 09/01/2002 - "Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies." 06/01/2003 - "BMS-184476 is a taxane analog under development by Bristol-Myers Squibb for the potential treatment of solid tumors. " 01/01/2001 - "Against the parental M109 tumor, both BMS-184476 and paclitaxel performed comparably. "
3.	Neutropenia 07/19/2004 - "Patients were enrolled at four dose levels: BMS-184476 (mg m(-2))/carboplatin (mg min ml(-1)): 40/5, 50/5, 50/6 and 60/6. Dose-limiting toxicity at 60/6 was neutropenia. " 05/01/2001 - "In contrast, of 15 assessable patients treated at the 60 mg/m2 dose level, which is the maximum-tolerated dose (MTD) of BMS-184476 on this administration schedule, only one heavily pretreated patient developed DLT (grade 4 neutropenia with fever and grade 3 diarrhea). " 11/01/2003 - "At the planned highest dose of BMS-184476 (60 mg/m(2)) and cisplatin (75 mg/m(2)), we observed dose-limiting toxicity in the form of neutropenia and diarrhea. "
4.	Diarrhea 05/01/2001 - "In contrast, of 15 assessable patients treated at the 60 mg/m2 dose level, which is the maximum-tolerated dose (MTD) of BMS-184476 on this administration schedule, only one heavily pretreated patient developed DLT (grade 4 neutropenia with fever and grade 3 diarrhea). " 11/01/2003 - "At the planned highest dose of BMS-184476 (60 mg/m(2)) and cisplatin (75 mg/m(2)), we observed dose-limiting toxicity in the form of neutropenia and diarrhea. "
5.	Sarcoma (Soft Tissue Sarcoma) 01/01/2001 - "BMS-184476 and paclitaxel were inactive in two murine model systems, M5076 sarcoma and the paclitaxel-resistant M109/txlr lung carcinoma. " 01/01/2001 - "Like paclitaxel and BMS-184476, BMS-188797 was inactive versus M5076 sarcoma. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	taxane
3.	BMS188797
4.	Taxoids (Taxanes)
5.	Carboplatin (JM8)
6.	Ether (Diethyl Ether)
7.	Cisplatin (Platino)
8.	Docetaxel (Taxotere)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Premedication
3.	Therapeutics
4.	Radiotherapy